Author: Vivian Xue  2nd April 2026

The US biopharmaceutical industry is at the forefront of innovation, driving advancements in healthcare while addressing the growing need for sustainability. As the global leader in biopharma, the US is uniquely positioned to set benchmarks for eco-friendly practices, including reducing carbon footprints, utilising sustainable materials, and implementing green manufacturing processes. These efforts are not only essential for environmental stewardship but also for ensuring the long-term viability of the industry. 

The US biopharmaceutical market is experiencing unprecedented growth. According to industry projections, “the US biopharmaceuticals market size was evaluated at US$185.45 billion in 2025 and is predicted to be worth around US$698.93 billion by 2035, rising at a CAGR of 14.19% from 2026 to 2035.” This rapid expansion underscores the need for sustainable practices to mitigate environmental impact while supporting the industry's growth trajectory. 

The 2025 Sustainability Report emphasizes the importance of sustainability in corporate operations, stating, as a core focus throughout many market leading organisations. This commitment reflects the growing recognition that sustainable practices are integral to long-term success. 

North America plays a dominant role in the global biopharmaceutical market, supported by increased investments by market players and supportive government policies in a huge market like the US. In fact, the US holds the intellectual property rights for the majority of newly produced medicines. These factors highlight the US's leadership role in the global biopharma sector and its responsibility to integrate sustainability into its operations. 

1. Reducing Carbon Footprints

The biopharma industry is a significant contributor to greenhouse gas emissions, with energy-intensive manufacturing processes and extensive supply chains. To address this, companies are adopting renewable energy sources, optimizing energy efficiency, and implementing carbon-neutral strategies. 

The 2025 Sustainability Report highlights that, “Carbon removal strategies seek to expand the voluntary carbon market towards projects that offer environmental and social benefits beyond carbon sequestration.” This approach demonstrates the industry's commitment to reducing emissions while creating additional environmental and social value. 

For example, many leading firms are transitioning to solar and wind energy to power their facilities. Additionally, digital technologies such as AI-driven supply chain optimization are helping to reduce waste and emissions. These efforts are critical for achieving net-zero goals and ensuring a sustainable future for the industry. Learn more about recycling single-use disposables in biopharma manufacturing.  

2. Utilizing Sustainable Materials 

The use of sustainable materials is a cornerstone of eco-friendly healthcare. Biopharma companies are increasingly adopting biodegradable and recyclable packaging solutions to minimize waste. This shift not only reduces environmental impact but also aligns with consumer preferences for sustainable products.  

As an example, the 2025 Sustainability Report notes that contributions to the sustainability of a watershed go beyond volumetric benefits and include capacity-building components for leading organizations in the watersheds where they operate. This focus on sustainable resource management underscores the importance of responsible material usage in biopharma operations. 

Innovations in drug delivery systems, such as plant-based capsules and reusable medical devices, are gaining traction. Furthermore, collaboration is now a key component in the search for sustainable materials. Companies are working closely with non-traditional partners and suppliers to ensure that raw materials are sourced responsibly, adhering to ethical and environmental standards. Discover how large pharma companies are making progress toward net zero. 

3. Implementing Green Manufacturing Processes 

Green manufacturing is revolutionizing the biopharma industry by reducing resource consumption and waste. Techniques such as continuous manufacturing and single-use bioreactors are enabling companies to produce pharmaceuticals more efficiently and sustainably. 

The 2025 Sustainability Report highlights the role of innovation in driving sustainability, with evaluations of potential and actual environmental and socioeconomic risks occurring at each stage of a project, including early stages of planning, to mitigate potential impacts. This proactive approach ensures that sustainability is embedded in every aspect of manufacturing. 

Continuous manufacturing streamlines production, eliminating the need for energy-intensive batch processing. Single-use bioreactors, made from recyclable materials, significantly reduce water and energy usage while maintaining high-quality standards. These innovations exemplify the industry's commitment to green manufacturing and its role in promoting eco-friendly healthcare. Explore how collaboration is pushing continuous manufacturing for sustainable biopharma. 

Industry Leaders Driving Change

Several U.S. biopharma companies are leading the charge in sustainability, setting benchmarks for eco-friendly practices. Companies like Pfizer, Amgen, and Biogen have implemented comprehensive sustainability programs that focus on reducing emissions, conserving resources, and promoting environmental stewardship. 

Pfizer: Committed to achieving carbon neutrality by 2030, Pfizer has invested in renewable energy and waste reduction initiatives. 

Amgen: Known for its green manufacturing technologies, Amgen has developed energy-efficient facilities and water conservation systems. 

Biogen: Recognized for its sustainability efforts, Biogen has integrated eco-friendly practices into its corporate strategy, earning accolades for its commitment to environmental responsibility. 

These companies are not only reducing their environmental impact but also inspiring others in the industry to follow suit. Learn more about scaling sustainability in big pharma. 

Government Policies and Support

The U.S. government plays a pivotal role in fostering sustainability within the biopharma sector. Policies such as tax incentives for renewable energy adoption and grants for green technology research encourage companies to invest in sustainable practices. Additionally, regulatory frameworks are evolving to prioritize environmental considerations, ensuring that sustainability becomes a core component of biopharma operations. 

Collaborations between government agencies and industry stakeholders are driving innovation in areas such as green manufacturing and sustainable materials. These partnerships are essential for creating a robust ecosystem that supports eco-friendly healthcare solutions. Discover more about biopharma trends shaping a sustainable future. 

Challenges and Opportunities

While the progress in sustainable biopharma is commendable, challenges remain. High upfront costs for green technologies, regulatory complexities, and the need for industry-wide collaboration are some of the hurdles that companies face. However, these challenges also present opportunities for innovation and growth. 

By investing in research and development, companies can discover new ways to enhance sustainability while maintaining profitability. Consumer demand for eco-friendly healthcare products is also driving change, encouraging companies to prioritize sustainability as a competitive advantage. 

The Future of Sustainable Biopharma 

As the U.S. biopharma industry continues to grow, sustainability will remain a key focus. The integration of eco-friendly practices, such as reducing carbon footprints, utilizing sustainable materials, and implementing green manufacturing processes, will shape the future of healthcare. By embracing these practices, American biopharma companies can lead the way in creating a healthier planet while delivering life-saving treatments. 

The 2025 Sustainability Report concludes, “Sustainability in the pharmaceutical industry is no longer a peripheral issue, but a central factor in shaping resilience, competitiveness, and trust.” This vision aligns with the industry's commitment to eco-friendly healthcare for all. 

The journey toward sustainable biopharma is not just an environmental imperative—it is a moral obligation. As stakeholders across the industry unite to address these challenges, the vision of eco-friendly healthcare becomes increasingly attainable. With continued innovation, collaboration, and commitment, the U.S. biopharma sector can set a global example for sustainability. 

Conclusion

Sustainability in U.S. biopharma operations is more than a trend; it is a transformative movement that aligns environmental responsibility with industry growth. By reducing carbon footprints, utilizing sustainable materials, and implementing green manufacturing processes, American biopharma companies are paving the way for a greener future. As the industry evolves, the commitment to eco-friendly healthcare will not only benefit the planet but also enhance the quality of life for generations to come.